Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 16,987

Document Document Title
WO/2009/068689A3
The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.  
WO/2009/069736A1
Disclosed is a nitrogenated compound represented by the formula (I) [wherein A represents an aryl which may have a substituent or the like; B's independently represent a hydrogen atom, a halogen or the like; n represents an integer of no...  
WO/2009/065854A1
This invention relates to N-acylhydrazone derivatives (I), which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the tre...  
WO/2009/066457A1
Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof ...  
WO/2009/062683A1
The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17- (OR4)-3-one structure for prophylactic and/or therapeutic uses, wherein R4 is hydrogen or an unsubstituted or subs...  
WO/2009/063993A1
Disclosed is a serotonin 5-HT2c receptor activator containing a compound represented by the formula (I) below or a salt thereof. (In the formula, the symbols are as defined in the description.)  
WO/2009/057086A1
The present invention provides R,R'-atracurium salts, processes for producing and purifying such salts, and methods of using such salts to produce highly pure cisatracurium besylate.  
WO/2009/054501A1
Use of a carbon dioxide-supplying unit for muscle strengthening makes it possible conveniently strengthen a target muscle within a short period of time merely by allowing the target site to absorb carbon dioxide without loading any a mec...  
WO/2009/054725A2
The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combine...  
WO/2009/054725A3
The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combine...  
WO/2009/051244A1
Disclosed is a compound represented by the following formula (I). (In the formula, the symbols are as defined in the description.) This compound has an excellent RBP4 lowering effect, and is useful as an agent for prevention or treatment...  
WO/2009/044383A1
The present invention relates to a nucleic acid molecule comprising a nucleotide sequence codifying for a protein characterized in having at least four zinc finger domains and in modulating the transcription of the utrophin gene by bindi...  
WO/2009/044787A1
It is clarified that the inhibition of the expression or function of tenomodulin induces a disease relating to the rupture of a tendon such as CTC. It is expected that tenomodulin protein or a substance capable of activating the expressi...  
WO/2009/044383A8
The present invention relates to a nucleic acid molecule comprising a nucleotide sequence codifying for a protein characterized in having at least four zinc finger domains and in modulating the transcription of the utrophin gene by bindi...  
WO/2009/040814A1
The invention provides an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide and a Copolymer 1-related polypeptide, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions...  
WO/2009/042907A1
Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 express...  
WO/2009/036590A1
The present invention relates to novel compounds from Antrodia cinnamomea and their use.  
WO/2009/038110A1
Disclosed is a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which comprises, as an active ingredient, any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms ...  
WO/2009/036149A9
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  
WO/2009/036149A3
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  
WO/2009/033250A1
A nutritional supplement comprising a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ing...  
WO/2009/036149A2
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  
WO/2009/033130A1
Compositions and methods for treating mitochondrial disorders are provided. The compositions include compounds having a mitochondrial targeting moiety, for example a lipophilic cation. Certain compounds are effective for increasing the r...  
WO/2009/025149A1
The object is to identify a receptor for ADNF to elucidate a specific signaling pathway of the anti-ALS activity of ADNF, and to provide a screening system for identifying a compound capable of binding to the ADNF receptor or a compound ...  
WO/2009/025091A1
Disclosed is a novel therapeutic agent for fibromyalgia. A pharmaceutical composition comprising tizanidine as an active ingredient can be used as a therapeutic agent for fibromyalgia. The pharmaceutical composition can ameliorate a pain...  
WO/2009/021750A3
There are disclosed compounds of Formula (1). Pharmaceutical compositions containing the compounds are also provided. Methods of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy and cachexia using the compounds and com...  
WO/2009/021747A3
There are provided compounds of Formula (I) wherein three of A1, A2, A3, and A4 represent CH and one of A1, A2, A3, and A4 represents CR1; R1 represents SO2R2 or NHCOR2 wherein R2 represents C1-C6 alkyl optionally substituted by one or m...  
WO/2009/021747A2
There are provided compounds of Formula (I) wherein three of A1, A2, A3, and A4 represent CH and one of A1, A2, A3, and A4 represents CR1; R1 represents SO2R2 or NHCOR2 wherein R2 represents C1-C6 alkyl optionally substituted by one or m...  
WO/2009/022687A1
Disclosed is a compound represented by the following general formula (I). (I) (In the formula, R1 represents a hydrogen atom or the like; R2 and R3 independently represent a hydrogen atom, an optionally oxidized C1-C4 alkyl group or an o...  
WO/2009/019027A1
Myogenesis in mammals can be promoted by a prenatal administration of 25-hydroxy vitamin D3 (25-OH D3). The 25-OH D3 can be administered to the pregnant mother, and the amount of muscle tissue in the offspring is increased relative to co...  
WO/2009/019505A3
Combinations comprising (or consisting essentially of) one or more compounds of the formula (I) or (II) with one or more ancillary compounds, to processes for preparing the combinations, and to various therapeutic uses of the combination...  
WO/2009/019505A2
Combinations comprising (or consisting essentially of) one or more compounds of the formula (I) or (II) with one or more ancillary compounds, to processes for preparing the combinations, and to various therapeutic uses of the combination...  
WO/2009/019815A1
Disclosed is a novel compound having excellent γ-secretase inhibitory activity and specifically inhibiting production of Aβ. Specifically disclosed is a compound represented by the formula (1) below or a pharmaceutically acceptable sal...  
WO/2009/016326A2
The present invention relates to a composition comprising: a first adeno-associated viral (AAV) vector comprising: i) a 5'ITR (Inverted Terminal Repeat) sequence of AAV; ii) a portion of gene placed under the control of a promoter; iii) ...  
WO/2009/013477A1
Compounds of general formula (I), wherein X1, X2, X3, R1, R2, R3, Y and Z are as defined herein are useful for the treatment and prevention of Duchenne muscular dystrophy, Becker muscular dystrophy and cachexia.  
WO/2009/013335A1
Compounds of formula (I) in free or salt or solvate form, where R1, R2 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions ...  
WO/2009/014127A1
Disclosed is a composition for the prevention or treatment of a disease associated with the production of an autoantibody. Specifically disclosed is a composition for the prevention or treatment of a disease associated with the productio...  
WO/2009/008529A1
It is intended to provide an antibody which binds specifically to an abnormal aggregate of TDP-43 protein. It is also intended to provide a drug for detecting a TDP-43 proteinopathy lesion which contains this antibody, a method of detect...  
WO/2009/008727A2
The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detect...  
WO/2009/008727A3
The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detect...  
WO/2009/008725A2
The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detect...  
WO/2009/008725A3
The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detect...  
WO/2009/004146A2
The invention relates to products having formula (I), in which A represents one of the following three rings: ring a, ring b, ring c and W represents hydrogen or -(C1-C4)alkyl, -(C1-C4)alkenyl, -CO-(C1-C3)alkyl, - CO-(C1-C3)alkenyl, -CO-...  
WO/2009/005033A1
It is intended to provide a substance which can be used as an active ingredient for improving dysfunction due to neuropathy. An agent for improving dysfunction due to neuropathy of the invention as a means for resolution is characterized...  
WO/2009/001915A1
Disclosed is a novel substituted imidazole compound having excellent renin inhibitory activity, which is sufficiently practical for use as a pharmaceutical product. Specifically disclosed is a compound represented by the formula (I) belo...  
WO/2008/155390A3
This invention relates to the use of inhibitors of sirtuins and/or AMPK for the preparation of a medicament for the treatment of polyalanine diseases, in particular oculopharyngeal musculardystrophy (OPMD). The invention also relates to ...  
WO/2008/156685A3
The invention relates to tendon stem cells useful for treating a variety of diseases and condition, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation...  
WO/2008/156513A3
Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new therapeutic target for the treatment of sk...  
WO/2008/156418A1
The present invention relates to methods for screening or diagnosis of Postpolio Syndrome (PPS) in subjects, for determining the stage or severity of PPS, for identifying subjects at risk of developing PPS, or for monitoring the effect o...  
WO/2008/156685A2
The invention relates to tendon stem cells useful for treating a variety of diseases and condition, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation...  

Matches 701 - 750 out of 16,987